Healthequity Inc (HQY) Investment Analysis:

1. Executive Summary:

Healthequity Inc (HQY) functions as the primary platform for the administration of health savings accounts (HSAs) and other consumer-directed benefits (CDBs) in the United States, operating as the dominant pure-play entity in a sector defined by the intersection of financial technology and healthcare reform. The company's core mission is to empower American healthcare consumers to save and invest for long-term medical expenses by providing a sophisticated technological ecosystem that connects health plans, employers, and individual members. As of the end of the fiscal year on January 31, 2025, HealthEquity administered 9.9 million HSAs with total assets under management reaching $32.1 billion, a figure that represents a significant 27% increase over the prior fiscal year. By October 31, 2025, these figures continued to expand, with the company managing 10.1 million HSAs and $34.4 billion in total HSA assets, further solidifying its market-leading position with an approximate 21% share of the total HSA asset market as of mid-2024.

The revenue model employed by HealthEquity is characterized by three highly predictable and recurring streams: custodial revenue, service revenue, and interchange revenue. Custodial revenue, which accounted for approximately 45.5% of total revenue in fiscal 2025, is generated from the interest rate spread on HSA cash balances held by depository and insurance company partners. Service revenue, contributing 39.9% in the same period, consists of monthly fees paid by employers (Clients) or individual members for account administration and investment advisory services. Interchange revenue, making up 14.7%, is derived from transaction fees processed when members utilize HealthEquity payment systems, such as physical or virtual debit cards, to pay for healthcare-related expenses.

HealthEquity’s distribution strategy relies on a multi-channel "business-to-business-to-consumer" (B2B2C) framework. The company partners with over 200 "Network Partners," including major health plans, benefit consultants, and retirement plan recordkeepers, which integrate HealthEquity’s platform into their own service offerings for employers. This integration creates a formidable competitive moat, as the platform becomes a critical component of the employer’s human resources and payroll infrastructure, leading to high retention rates and low customer churn. The company serves a diverse customer base ranging from individual consumers to Fortune 100 enterprises, managing a total of 17.0 million accounts when including complementary benefits such as Flexible Spending Accounts (FSAs) and Health Reimbursement Arrangements (HRAs).

The strategic landscape for HealthEquity is currently being reshaped by significant legislative catalysts, most notably the "One Big Beautiful Bill Act" passed in July 2025, which is projected to expand the total addressable market (TAM) for HSAs to its largest extent in two decades by making millions of additional families eligible for tax-advantaged accounts through ACA Bronze and Catastrophic plans starting in 2026.

2. Business Drivers & Strategic Overview:

The fundamental driver of HealthEquity’s growth is the ongoing structural transition of the U.S. commercial health insurance market toward High Deductible Health Plans (HDHPs) paired with HSAs. This shift is motivated by the persistent need for employers to mitigate the rising cost of premiums and the growing recognition of the HSA as a vital long-term retirement and wealth management tool due to its unique triple tax advantage: contributions are tax-deductible, growth is tax-free, and withdrawals for qualified medical expenses are tax-free.

The Growth Flywheel: Account, Asset, and Yield Optimization

The company’s strategic objective is centered on a "flywheel" effect that begins with account acquisition and extends through the lifecycle of the member’s healthcare saving journey.

First, HealthEquity leverages its 200+ Network Partners and direct sales force to drive account growth. Approximately two out of every three new HSAs are generated from existing client relationships, indicating a high level of efficiency in the sales process and the value of deeply embedded partnerships. Second, as accounts age, members tend to accumulate higher balances. Data shows a clear correlation between account age and balance size, with funded accounts opened in 2004 averaging $33,010 compared to $1,723 for those opened in the first half of 2025. Third, as members reach a certain threshold—typically $1,000 to $2,000 in cash—they begin to transition from "savers" to "investors". This transition is a critical revenue driver, as accounts with investments average $22,635 in combined assets, nine times the $2,469 average for deposit-only accounts. In the third quarter of fiscal 2026, HSA investment assets grew 29% year-over-year to $17.5 billion, outpacing the 6% growth in account numbers.

Legislative Catalysts: The One Big Beautiful Bill Act (OBBBA)

The most significant near-term strategic catalyst is the passage of the One Big Beautiful Bill Act in July 2025, which introduces landmark provisions that expand HSA utility and eligibility. Starting in 2026, the legislation allows Affordable Care Act (ACA) Bronze and Catastrophic plans to be compatible with HSAs, potentially adding millions of new participants who were previously excluded from the tax-advantaged savings ecosystem. Furthermore, the bill allows HSA funds to be used for Direct Primary Care (DPC) membership fees up to $150 per month, addressing a major historical barrier to HSA-DPC integration.

Competitive Advantages and Competitive Landscape

HealthEquity maintains a competitive advantage through its scale, proprietary technological platform, and high switching costs. As the largest custodian, the company benefits from fixed-cost leverage; its operating expenses as a percentage of revenue have consistently improved as the asset base has grown. The platform’s integration with payroll systems and health plans makes it difficult for employers to switch providers, a fact reflected in HealthEquity's high member retention rates.

In the competitive landscape, HealthEquity faces challenges from established financial giants like Fidelity and vertically integrated players like Optum (UnitedHealth Group). Fidelity is noted for having lower fees and higher interest rates on uninvested cash (2.19% compared to the industry average of <1%), which has made it a favorite for "long-term savers" who prioritize investment features. Optum, conversely, leverages its massive captive insurance base to drive HSA adoption. HealthEquity differentiates itself by remaining an independent, pure-play custodian that can partner with any health plan, providing "AutoPilot" and "GPS" advisory services that are specifically tailored to healthcare financial literacy.

Strategic Acquisitions and Portfolio Growth

Inorganic growth remains a cornerstone of the HealthEquity strategy. The fiscal 2025 acquisition of the BenefitWallet HSA portfolio for $425 million added approximately 616,000 HSAs and $2.7 billion in assets, illustrating the company's ability to consolidate the market. These acquisitions allow HealthEquity to rapidly scale its "enhanced rates" program, where HSA cash is placed with insurance company partners to achieve higher yields than traditional bank deposits. This strategy has been a primary driver of the 41% increase in custodial revenue seen in fiscal 2025.

3. Financial Performance & Valuation:

Recent Historical Performance (Fiscal 2025 - 2026)

HealthEquity's financial performance in fiscal 2025 and the first three quarters of fiscal 2026 has been marked by strong top-line growth and significant margin expansion. For the fiscal year ended January 31, 2025, total revenue grew 20% to $1.199 billion. This growth was heavily weighted toward custodial revenue, which benefited from a rising interest rate environment and a 15% increase in average daily HSA cash balances.

In the third quarter of fiscal 2026 (ended October 31, 2025), HealthEquity reported revenue of $322.2 million, an increase of 7% year-over-year. While service revenue growth has moderated (+1% in Q3 FY26), custodial revenue continued to grow at a double-digit clip (+13%), driven by yield optimization and a 15% increase in total HSA assets to $34.4 billion.

The company's profitability has surged, with GAAP net income increasing 806% in the third quarter of fiscal 2026 compared to the same period in the prior year, though this was partly due to a one-time legal settlement in the previous year's base. Gross margins reached an impressive 71% in Q3 FY26, highlighting the inherent scalability of the custodial revenue stream as yields reprice into higher-rate contracts.

Valuation Multiples and Market Perception

As of early February 2026, the market valuation of HealthEquity presents a complex picture of a high-growth company trading at historically moderate multiples due to interest rate sensitivities. With a current share price of approximately $79.28 to $79.45, the company has a market capitalization of roughly $6.8 billion to $7.3 billion.

• Price-to-Earnings (P/E) Ratio: The forward P/E ratio is approximately 20.8x based on fiscal 2026 non-GAAP EPS estimates of ~$3.90. This is near the company's 5-year low, suggesting a potential compression in valuation that may not account for the OBBBA expansion.

• Price-to-Sales (P/S) Ratio: The stock trades at approximately 5.1x to 6.9x revenue, which is lower than many high-growth SaaS peers in the healthcare space.

• EV/Adjusted EBITDA: Trading at roughly 15.1x fiscal 2026 EBITDA estimates.

• P/E/G Ratio: Currently stands at 0.99, indicating the stock may be undervalued relative to its expected double-digit earnings growth.

Analysts are divided on the valuation. While the average price target remains high at $118.40 to $121.36, representing over 50% upside, Goldman Sachs recently downgraded the stock to a "Strong Sell" with a $89 price target, citing concerns over the durability of the custodial yield and competitive pressures from lower-cost providers like Fidelity.

Capital Structure and Allocation

HealthEquity maintains a solid financial position, exiting Q2 FY2026 with $304.5 million in cash and cash equivalents. Total debt stands at approximately $1.01 billion, following the establishment of a $1.0 billion revolving credit facility in August 2024. Management has demonstrated a commitment to returning capital to shareholders, repurchasing 1.0 million shares for $93.7 million in the third quarter of fiscal 2026 alone. As of October 31, 2025, $258.8 million remained authorized for future repurchases. This buyback activity, combined with debt reduction using robust operational cash flows ($339 million in the first nine months of FY26), underscores a disciplined capital allocation strategy.

4. Risk Assessment & Macroeconomic Considerations:

Interest Rate Sensitivity and Custodial Spread Risks

The primary macroeconomic risk facing HealthEquity is a potential decline in the federal funds rate. Because custodial revenue (the company's most profitable segment) is derived from the spread earned on HSA cash balances, a lower interest rate environment directly reduces the income earned on uninvested cash and client-held funds. To mitigate this, the company utilizes 5-year Treasury bond hedges and fixed-rate contracts. As of October 31, 2025, HealthEquity had a cumulative $2.25 billion hedge at a 3.94% rate. However, the company remains exposed to the "repricing schedule" of its $16.4 billion in fixed-rate contracts; if market rates fall significantly before these contracts mature, the replacement yields will be lower, creating a headwind for custodial revenue growth.

Legislative and Regulatory Risks

HealthEquity’s business model is predicated on the tax-advantaged status of HSAs as defined in the Internal Revenue Code. Any legislative changes that reduce these tax benefits, cap contributions, or significantly restructure the Affordable Care Act could materially impact the demand for HSAs. While the "One Big Beautiful Bill Act" currently provides a tailwind, a shift in political power could lead to a reversal of these provisions or a shift toward "Medicare for All" style healthcare systems that could eliminate the role of private custodians. Furthermore, the company must manage complex compliance requirements across various states and federal agencies, making it vulnerable to regulatory enforcement actions or increased compliance costs.

Credit and Operational Risks

A specific operational risk is the "Enhanced Rates" program, where HSA cash is placed with insurance company partners to achieve higher yields. Unlike cash held by depository partners, these funds are not federally insured, meaning HealthEquity's members bear the risk of loss if an insurance partner fails. Additionally, the company has seen an increase in costs related to protecting members from outside fraud activity, which totaled $0.3 million in Q3 FY26. A significant cybersecurity breach or a loss of custodial assets due to a partner failure would cause catastrophic reputational damage and likely lead to massive account outflows.

Competitive and Market Risks

The HSA market is increasingly competitive, with large financial institutions like Fidelity and Bank of America offering integrated wealth management solutions. Fidelity’s decision to offer zero-fee HSAs and significantly higher interest rates on cash (2.19% vs. HealthEquity's <1% for many tiers) poses a threat to HealthEquity's ability to attract and retain "long-term savers" who are more sensitive to fees and yields. Furthermore, the trend toward higher HSA investment adoption—while beneficial for asset growth—reduces the amount of cash available for HealthEquity to earn a spread on, potentially shifting the revenue mix toward lower-margin service fees.

5. 5-Year Scenario Analysis:

This analysis projects the trajectory of HealthEquity from Fiscal Year 2027 through Fiscal Year 2031, incorporating the impact of the OBBBA, interest rate cycles, and market share dynamics.

Current Market Context

• Current Share Price (Feb 2026): ~$79.45.

• FY2026 Non-GAAP EPS (Guide): $3.91.

• FY2027 Revenue (Guide): $1.38B - $1.41B.

Scenario 1: Base Case (55% Probability)

In the base case, the "One Big Beautiful Bill Act" leads to a steady expansion of the TAM. HealthEquity maintains its 21% market share of assets and grows its account base at a 6-7% CAGR. Interest rates remain "higher for longer," allowing the company to replace maturing custodial contracts at yields between 3.5% and 4.0%. The transition of members to investors continues at a steady pace, with invested assets reaching 50% of total assets by 2031.

• 5-Year Sales Growth: 10.5% CAGR.

• EBITDA Margins: Expand to 45% due to technological efficiency and scale.

• Custodial Yield: Averages 3.75%.

• FY2031 Revenue: $2.14 Billion.

• FY2031 Non-GAAP EPS: $6.75.

• Assumed P/E Multiple: 22x (Historical average for mature growth fintech).

Projected FY2031 Share Price: $148.50

Scenario 2: High Case (25% Probability)

The OBBBA triggers a "tipping point" in HSA adoption, similar to the 401(k) boom of the 1990s. Millions of Bronze plan holders flood into HSAs, and contribution limits are increased significantly. HealthEquity captures a higher share of the investment market through its AutoPilot AI tools. Interest rates rise or stay elevated, and the company’s "Enhanced Rates" program generates superior spreads without credit events.

• 5-Year Sales Growth: 15.0% CAGR.

• EBITDA Margins: Expand to 48%.

• Custodial Yield: Averages 4.5%.

• FY2031 Revenue: $2.63 Billion.

• FY2031 Non-GAAP EPS: $9.15.

• Assumed P/E Multiple: 28x (Reflecting market leader premium and high growth).

Projected FY2031 Share Price: $256.20

Scenario 3: Low Case (20% Probability)

A sharp economic recession leads to massive Fed rate cuts (to <1%), decimating custodial revenue. Competition from Fidelity and other zero-fee providers forces HealthEquity to eliminate its administration fees for many segments, leading to service revenue contraction. Regulatory pushback limits the utility of the OBBBA, and HSA adoption plateaus as employers move back toward traditional HMO plans to simplify costs.

• 5-Year Sales Growth: 4.0% CAGR.

• EBITDA Margins: Contract to 34% due to fee compression.

• Custodial Yield: Drops to 1.5%.

• FY2031 Revenue: $1.58 Billion.

• FY2031 Non-GAAP EPS: $3.10.

• Assumed P/E Multiple: 15x (Reflecting a slow-growth "legacy" financial services multiple).

Projected FY2031 Share Price: $46.50

Share Price Trajectory Table (5-Year Projections)

Probability Weighted Outcome

• Weighted Price Target: ($148.50 0.55) + ($256.20 0.25) + ($46.50 * 0.20) = $155.03

• Total Potential Return from ~$79.45: +95.1%

STRUCTURAL FINTECH DOMINANCE

6. Qualitative Scorecard:

Metric Ratings and Narratives

• Management Alignment: 8/10 HealthEquity’s leadership, recently transitioned to CEO Scott Cutler, remains heavily incentivized through equity-based compensation tied to Adjusted EBITDA and Total Shareholder Return (TSR). The presence of founder Stephen Neeleman as Vice Chairman provides strategic continuity. However, recent insider selling by multiple EVPs in late 2025 and January 2026, totaling approximately $1.3 million, reflects a minor degree of short-term profit-taking that warrants monitoring.

• Revenue Quality: 9/10 The business model is highly resilient, with approximately 85% of revenue being recurring in nature. HSAs are "sticky" accounts; once established with an employer’s payroll, the switching costs are high, and the account typically stays with the member for decades.

• Market Position: 10/10 HealthEquity is the clear winner in the HSA consolidation race, having grown its market share from 4% in 2010 to 21% today. They are the largest custodian by both accounts and assets, giving them superior bargaining power with Network Partners.

• Growth Outlook: 9/10 The OBBBA legislative catalyst creates a powerful multi-year tailwind. The shift toward HSAs as a "healthcare 401(k)" is still in its early innings, with only 10% of accounts currently holding investments, leaving massive room for asset expansion.

• Financial Health: 8/10 The company maintains strong liquidity with a current ratio of 4.13 and robust free cash flow generation (FCF/Rev LTM of 28%). Debt is manageable at 0.46x equity, though interest rate sensitivity remains the primary "hidden" liability on the revenue side.

• Business Viability: 9/10 The durability of the HSA as a tax-advantaged vehicle is core to the U.S. healthcare strategy of both political parties. The "choke point" is the dependency on HDHPs, but given current employer cost trends, the move away from HDHPs seems unlikely.

• Capital Allocation: 8/10 Management has demonstrated an expert ability to integrate large acquisitions like WageWorks and BenefitWallet. The pivot toward share repurchases in FY2026 suggests they recognize the current valuation gap.

• Analyst Sentiment: 7/10 Sentiment is currently a "Moderate Buy" but is fragmented. The recent Goldman Sachs downgrade to "Strong Sell" has created a cloud over the stock, with concerns focused on the "cautious 2027 outlook" providing a shorter-term headwind to sentiment.

• Profitability: 9/10 With gross margins above 70% and EBITDA margins trending toward 44%, HealthEquity exhibits high-software-like profitability on a financial services asset base.

• Track Record: 10/10 The company has a consistent history of meeting or exceeding growth targets and successfully navigating various interest rate cycles (including the zero-rate COVID era) while expanding market share.

Overall Blended Score: 8.7 / 10

BEST IN CLASS

7. Conclusion & Investment Thesis:

HealthEquity occupies a unique and dominant position as the "toll booth" for the modern American health savings ecosystem. The investment thesis is predicated on the confluence of three powerful factors: the structural shift toward high-deductible health plans, the increasing use of HSAs as long-term investment vehicles, and the massive TAM expansion provided by the One Big Beautiful Bill Act of 2025.

While the stock has recently faced technical pressure and a downgrade from a major investment bank, the underlying fundamentals suggest the company is currently undervalued relative to its 5-year earnings potential. The transition from a spread-based custodial model to a diversified fintech platform with high-margin investment fees provides a pathway for sustained double-digit earnings growth. The primary risk remains interest rate volatility, but the company's aggressive hedging and "Enhanced Rates" strategies provide a significant buffer. As the market begins to price in the 2026 expansion of HSA eligibility to marketplace families and the integration of Direct Primary Care, HealthEquity's "flywheel" is poised to accelerate.

SCALABLE HEALTHCARE FINTECH

8. Technical Analysis, Price Action & Short-Term Outlook:

HealthEquity is currently exhibiting bearish technical momentum, trading at approximately $79, which is well below its 200-day moving average of $94.78 and its 50-day moving average of $91.48. The stock entered "oversold territory" in mid-January 2026 following a 10% single-day drop triggered by a Goldman Sachs downgrade and a 2027 revenue outlook that slightly missed analyst expectations. While the RSI of 32.53 suggests a potential for a short-term relief rally, the broader trend remains negative until the stock can successfully reclaim and consolidate above the $85 level. The short-term outlook is cautious as the market waits for more clarity on the 2026 OBBBA implementation.

OVERSOLD BEARISH TREND